vs
Northwest Bancshares, Inc.（NWBI）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Northwest Bancshares, Inc.的1.3倍（$219.9M vs $175.1M），Northwest Bancshares, Inc.净利率更高（28.9% vs -1.0%，领先29.9%），过去两年Northwest Bancshares, Inc.的营收复合增速更高（33.7% vs 8.0%）
西北银行是总部位于美国宾夕法尼亚州沃伦的金融机构，为银行控股公司西北银行股份有限公司（Northwest Bancshares, Inc.）的核心子公司，在宾夕法尼亚州、纽约州西部、俄亥俄州东北部、俄亥俄州阿巴拉契亚区域及印第安纳州共运营151家分支机构。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NWBI vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$175.1M
净利率更高
NWBI
高出29.9%
-1.0%
两年增速更快
NWBI
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $175.1M | $219.9M |
| 净利润 | $50.5M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 28.9% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | 10.6% | 92.4% |
| 每股收益（稀释后） | $0.34 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NWBIOFIX
| Q1 26 | $175.1M | — | ||
| Q4 25 | $179.9M | $219.9M | ||
| Q3 25 | $168.2M | $205.6M | ||
| Q2 25 | $150.4M | $203.1M | ||
| Q1 25 | $156.2M | $193.6M | ||
| Q4 24 | $154.3M | $215.7M | ||
| Q3 24 | $139.1M | $196.6M | ||
| Q2 24 | $98.0M | $198.6M |
净利润NWBIOFIX
| Q1 26 | $50.5M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $3.2M | $-22.8M | ||
| Q2 25 | $33.7M | $-14.1M | ||
| Q1 25 | $43.5M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $33.6M | $-27.4M | ||
| Q2 24 | $4.7M | $-33.4M |
毛利率NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 32.6% | 0.2% | ||
| Q3 25 | 2.1% | -8.3% | ||
| Q2 25 | 29.3% | -7.9% | ||
| Q1 25 | 36.2% | -25.2% | ||
| Q4 24 | 27.5% | -5.3% | ||
| Q3 24 | 31.3% | -9.6% | ||
| Q2 24 | 6.1% | -12.5% |
净利率NWBIOFIX
| Q1 26 | 28.9% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 1.9% | -11.1% | ||
| Q2 25 | 22.4% | -6.9% | ||
| Q1 25 | 27.8% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 24.2% | -13.9% | ||
| Q2 24 | 4.8% | -16.8% |
每股收益（稀释后）NWBIOFIX
| Q1 26 | $0.34 | — | ||
| Q4 25 | $0.30 | $-0.05 | ||
| Q3 25 | $0.02 | $-0.57 | ||
| Q2 25 | $0.26 | $-0.36 | ||
| Q1 25 | $0.34 | $-1.35 | ||
| Q4 24 | $0.26 | $-0.76 | ||
| Q3 24 | $0.26 | $-0.71 | ||
| Q2 24 | $0.04 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $286.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $450.0M |
| 总资产 | $16.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NWBIOFIX
| Q1 26 | $286.7M | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益NWBIOFIX
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $450.0M | ||
| Q3 25 | $1.9B | $442.5M | ||
| Q2 25 | $1.6B | $458.3M | ||
| Q1 25 | $1.6B | $458.3M | ||
| Q4 24 | $1.6B | $503.1M | ||
| Q3 24 | $1.6B | $525.9M | ||
| Q2 24 | $1.6B | $546.0M |
总资产NWBIOFIX
| Q1 26 | $16.9B | — | ||
| Q4 25 | $16.8B | $850.6M | ||
| Q3 25 | $16.4B | $832.6M | ||
| Q2 25 | $14.5B | $837.2M | ||
| Q1 25 | $14.5B | $823.1M | ||
| Q4 24 | $14.4B | $893.3M | ||
| Q3 24 | $14.4B | $867.9M | ||
| Q2 24 | $14.4B | $882.0M |
负债/权益比NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | $153.4M | $27.7M | ||
| Q3 25 | $41.9M | $12.4M | ||
| Q2 25 | $-2.3M | $11.6M | ||
| Q1 25 | $107.6M | $-18.4M | ||
| Q4 24 | $127.7M | $23.7M | ||
| Q3 24 | $93.3M | $11.7M | ||
| Q2 24 | $40.7M | $9.0M |
自由现金流NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | $141.8M | $16.8M | ||
| Q3 25 | $38.3M | $2.5M | ||
| Q2 25 | $-6.0M | $4.5M | ||
| Q1 25 | $105.8M | $-25.1M | ||
| Q4 24 | $125.4M | $15.2M | ||
| Q3 24 | $93.2M | $6.3M | ||
| Q2 24 | $37.2M | $-360.0K |
自由现金流率NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 78.8% | 7.6% | ||
| Q3 25 | 22.8% | 1.2% | ||
| Q2 25 | -4.0% | 2.2% | ||
| Q1 25 | 67.7% | -13.0% | ||
| Q4 24 | 81.3% | 7.0% | ||
| Q3 24 | 67.0% | 3.2% | ||
| Q2 24 | 37.9% | -0.2% |
资本支出强度NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | 6.5% | 4.9% | ||
| Q3 25 | 2.2% | 4.8% | ||
| Q2 25 | 2.4% | 3.5% | ||
| Q1 25 | 1.2% | 3.5% | ||
| Q4 24 | 1.5% | 4.0% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 3.6% | 4.7% |
现金转化率NWBIOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 13.24× | — | ||
| Q2 25 | -0.07× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.77× | — | ||
| Q2 24 | 8.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NWBI
| Net Interest Income | $142.5M | 81% |
| Noninterest Income | $32.6M | 19% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
